Related Experiment Video
Updated: Aug 12, 2026
05:42
The Forced Swim Test as a Model of Depressive-like Behavior
Published on: March 2, 2015
Accommodation to serotonin reuptake inhibitor-induced sexual dysfunction
1State University of New York, Buffalo Medical School, New York, USA.
Journal of Sex & Marital Therapy
|July 22, 1998
Summary
Sexual dysfunction from serotonin reuptake inhibitors (SRIs) is common, but spontaneous improvement is rare. A study of 132 trials found only 9.8% showed accommodation to this side effect, suggesting it
Area of Science:
- Psychiatry
- Pharmacology
Background:
- Selective serotonin reuptake inhibitors (SRIs) are widely prescribed antidepressants.
- Sexual dysfunction is a frequent and distressing side effect of SRI treatment.
- The potential for spontaneous remission or accommodation to SRI-induced sexual dysfunction is not well-established.
Purpose of the Study:
- To investigate the phenomenon of accommodation to serotonin reuptake inhibitor-induced sexual dysfunction.
- To quantify the rate of spontaneous remission of sexual side effects in patients taking SRIs.
Main Methods:
- A meta-analysis of 132 medication trials involving 97 patients was conducted.
- Data on the occurrence and duration of sexual dysfunction during SRI treatment were extracted and analyzed.
Main Results:
- Accommodation to SRI-induced sexual dysfunction was observed in only 9.8% of the analyzed medication trials.
- This suggests that spontaneous remission of sexual dysfunction is an uncommon outcome for patients on SRIs.
Conclusions:
- Clinicians should be aware that accommodation to SRI-induced sexual dysfunction is a rare event.
- Waiting for spontaneous remission may not be an effective strategy for managing this common side effect.
- Further research into effective management strategies for SRI-induced sexual dysfunction is warranted.
More Related Videos
04:22Treatment Model for Young Patients with Psychogenic Erectile Dysfunction and Resultant Infertility
Published on: May 30, 2025
08:15Network Pharmacology and Validation of the Antidepressant Mechanisms of Qiangzhifang in a Chronic Restraint Stress-induced Depression Rat Model
Published on: June 6, 2025
Related Concept Videos
01:21G-protein Coupled Receptors
G-protein coupled receptors are ligand binding receptors that indirectly affect changes in the cell. The actual receptor is a single polypeptide that transverses the cell membrane seven times creating intracellular and extracellular loops. The extracellular loops create a ligand specific pocket which binds to neurotransmitters or hormones. The intracellular loops holds onto the G-protein.
01:25Antidepressant Drugs: Overview
Antidepressant drugs are a class of medications primarily used for treating various mood disorders, including major depression, anxiety disorders, and other related conditions. These medicines work by modulating the neurotransmitter balance within the brain, alleviating depressive symptoms. Antidepressants can be broadly categorized into several groups according to their mechanism of action and chemical structure: Selective Serotonin Reuptake Inhibitors (SSRIs), Serotonin-Norepinephrine...
01:28Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs
Tricyclic Antidepressants (TCAs), including Desipramine (Norpramin), Imipramine (Tofranil), Clomipramine (Anafranil), and Amitriptyline (Elavil), inhibit serotonin and norepinephrine reuptake and also block other receptors. They are used for depression, pain conditions, and insomnia. Common adverse effects include anticholinergic effects, sedation, orthostatic hypotension, and weight gain. They have a narrow therapeutic window and so require plasma-level monitoring. Abrupt discontinuation can...
01:23Antidepressant Drugs: MAOIs and Other Agents
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
01:23Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists
Serotonin, a crucial neurotransmitter synthesized by enterochromaffin cells, plays a cardinal role in regulating gastrointestinal (GI) motility. With over 90% of the body's total serotonin in the GI tract, its influence on digestive processes is profound. Serotonin is swiftly released upon various stimuli, such as food boluses or certain drugs, triggering intrinsic sensory neurons in the myenteric plexus and extrinsic vagal and spinal sensory neurons. This leads to the activation of the...
01:08Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...